Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells
Phase 2
Not yet recruiting
- Conditions
- Corona Virus InfectionCovid19
- Interventions
- Biological: Allogeneic adipose-derived stem cells
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Celltex Therapeutics Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT05017298
Autologous Human Adipose-Derived Mesenchymal Stem Cells in Alzheimer's Disease
- Conditions
- Alzheimer Disease
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Celltex Therapeutics Corporation
- Registration Number
- NCT04855955
Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis
Phase 2
Not yet recruiting
- Conditions
- Osteoarthritis, HipOsteoarthritis ShoulderOsteoarthritis, Knee
- Interventions
- Biological: Celltex- AdMSCs
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Celltex Therapeutics Corporation
- Target Recruit Count
- 300
- Registration Number
- NCT04448106
- Locations
- 🇺🇸
Stanley C Jones, Houston, Texas, United States
Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19
Phase 2
Not yet recruiting
- Conditions
- COVID-19
- Interventions
- Biological: autologous adipose-derived stem cells
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Celltex Therapeutics Corporation
- Target Recruit Count
- 200
- Registration Number
- NCT04428801
Autologous Adipose-derived Stem Cells (AdMSCs) for Rheumatoid Arthritis
Phase 1
Not yet recruiting
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: autologous adipose derived stem cells
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Celltex Therapeutics Corporation
- Target Recruit Count
- 54
- Registration Number
- NCT04170426
© Copyright 2025. All Rights Reserved by MedPath